36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE
Issued Date
2023-02-01
Resource Type
ISSN
00493848
eISSN
18792472
Scopus ID
2-s2.0-85144538710
Pubmed ID
36565677
Journal Title
Thrombosis Research
Volume
222
Start Page
31
End Page
39
Rights Holder(s)
SCOPUS
Bibliographic Citation
Thrombosis Research Vol.222 (2023) , 31-39
Suggested Citation
Turpie A.G.G., Farjat A.E., Haas S., Ageno W., Weitz J.I., Goldhaber S.Z., Goto S., Angchaisuksiri P., Kayani G., Lopes R.D., Chiang C.E., Gibbs H., Verhamme P., ten Cate H., Muntaner J., Schellong S., Bounameaux H., Prandoni P., Kakkar A.K., Loualidi A., Colak A., Bezuidenhout A., Abdool-Carrim A., Azeddine A., Beyers A., Dees A., Mohamed A., Aksoy A., Abiko A., Watanabe A., Krichell A., Fernandez A.A., Tosetto A., Khotuntsov A., Oropallo A., Slocombe A., Kelly A., Clark A., Gad A., Arouni A., Schmidt A., Berni A., Kleiban A.J., Machowski A., Kazakov A., Galvez A., Lockman A., Falanga A., Chauhan A., Riera-Mestre A., Mazzone A., D'Angelo A., Herdy A., Kato A., Salem A.A.E.E.M., Husin A., Erdelyi B., Jacobson B., Amann-Vesti B., Battaloglu B., Wilson B., Cosmi B., Francois B.J., Toufek B., Hunt B., Natha B., Mustafa B., Kho B.C.S., Carine B., Zidel B., Dominique B., Christophe B., Trimarco B., Luo C., Cuneo C.A., Diaz C.J.S., Schwencke C., Cader C., Yavuz C., Zaidman C.J., Lunn C., Wu C.C., Toh C.H., Elisa C., Hsia C.H., Huang C.L., Kwok C.H.K., Wu C.C., Huang C.H., Ward C., Opitz C., Jeanneret-Gris C., Ha C.Y., Huang C.Y., Bidi C.L., Smith C., Brauer C., Lodigiani C., Francis C., Wu C. 36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE. Thrombosis Research Vol.222 (2023) , 31-39. 39. doi:10.1016/j.thromres.2022.11.016 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82435
Title
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE
Author(s)
Turpie A.G.G.
Farjat A.E.
Haas S.
Ageno W.
Weitz J.I.
Goldhaber S.Z.
Goto S.
Angchaisuksiri P.
Kayani G.
Lopes R.D.
Chiang C.E.
Gibbs H.
Verhamme P.
ten Cate H.
Muntaner J.
Schellong S.
Bounameaux H.
Prandoni P.
Kakkar A.K.
Loualidi A.
Colak A.
Bezuidenhout A.
Abdool-Carrim A.
Azeddine A.
Beyers A.
Dees A.
Mohamed A.
Aksoy A.
Abiko A.
Watanabe A.
Krichell A.
Fernandez A.A.
Tosetto A.
Khotuntsov A.
Oropallo A.
Slocombe A.
Kelly A.
Clark A.
Gad A.
Arouni A.
Schmidt A.
Berni A.
Kleiban A.J.
Machowski A.
Kazakov A.
Galvez A.
Lockman A.
Falanga A.
Chauhan A.
Riera-Mestre A.
Mazzone A.
D'Angelo A.
Herdy A.
Kato A.
Salem A.A.E.E.M.
Husin A.
Erdelyi B.
Jacobson B.
Amann-Vesti B.
Battaloglu B.
Wilson B.
Cosmi B.
Francois B.J.
Toufek B.
Hunt B.
Natha B.
Mustafa B.
Kho B.C.S.
Carine B.
Zidel B.
Dominique B.
Christophe B.
Trimarco B.
Luo C.
Cuneo C.A.
Diaz C.J.S.
Schwencke C.
Cader C.
Yavuz C.
Zaidman C.J.
Lunn C.
Wu C.C.
Toh C.H.
Elisa C.
Hsia C.H.
Huang C.L.
Kwok C.H.K.
Wu C.C.
Huang C.H.
Ward C.
Opitz C.
Jeanneret-Gris C.
Ha C.Y.
Huang C.Y.
Bidi C.L.
Smith C.
Brauer C.
Lodigiani C.
Francis C.
Wu C.
Farjat A.E.
Haas S.
Ageno W.
Weitz J.I.
Goldhaber S.Z.
Goto S.
Angchaisuksiri P.
Kayani G.
Lopes R.D.
Chiang C.E.
Gibbs H.
Verhamme P.
ten Cate H.
Muntaner J.
Schellong S.
Bounameaux H.
Prandoni P.
Kakkar A.K.
Loualidi A.
Colak A.
Bezuidenhout A.
Abdool-Carrim A.
Azeddine A.
Beyers A.
Dees A.
Mohamed A.
Aksoy A.
Abiko A.
Watanabe A.
Krichell A.
Fernandez A.A.
Tosetto A.
Khotuntsov A.
Oropallo A.
Slocombe A.
Kelly A.
Clark A.
Gad A.
Arouni A.
Schmidt A.
Berni A.
Kleiban A.J.
Machowski A.
Kazakov A.
Galvez A.
Lockman A.
Falanga A.
Chauhan A.
Riera-Mestre A.
Mazzone A.
D'Angelo A.
Herdy A.
Kato A.
Salem A.A.E.E.M.
Husin A.
Erdelyi B.
Jacobson B.
Amann-Vesti B.
Battaloglu B.
Wilson B.
Cosmi B.
Francois B.J.
Toufek B.
Hunt B.
Natha B.
Mustafa B.
Kho B.C.S.
Carine B.
Zidel B.
Dominique B.
Christophe B.
Trimarco B.
Luo C.
Cuneo C.A.
Diaz C.J.S.
Schwencke C.
Cader C.
Yavuz C.
Zaidman C.J.
Lunn C.
Wu C.C.
Toh C.H.
Elisa C.
Hsia C.H.
Huang C.L.
Kwok C.H.K.
Wu C.C.
Huang C.H.
Ward C.
Opitz C.
Jeanneret-Gris C.
Ha C.Y.
Huang C.Y.
Bidi C.L.
Smith C.
Brauer C.
Lodigiani C.
Francis C.
Wu C.
Author's Affiliation
Ramathibodi Hospital
National Yang Ming Chiao Tung University
Departement Cardiovasculaire Wetenschappen
Thrombosis & Atherosclerosis Research Institute
Bayer plc, UK
McMaster University
Duke Clinical Research Institute
Tokai University School of Medicine
Technische Universität München
Brigham and Women's Hospital
Thrombosis Research Institute
The Alfred
Maastricht Universitair Medisch Centrum+
Università degli Studi dell'Insubria
Universidad Nacional de Tucuman (UNT)
Faculty of Medicine
Municipal Hospital Dresden
Arianna Foundation on Anticoagulation
National Yang Ming Chiao Tung University
Departement Cardiovasculaire Wetenschappen
Thrombosis & Atherosclerosis Research Institute
Bayer plc, UK
McMaster University
Duke Clinical Research Institute
Tokai University School of Medicine
Technische Universität München
Brigham and Women's Hospital
Thrombosis Research Institute
The Alfred
Maastricht Universitair Medisch Centrum+
Università degli Studi dell'Insubria
Universidad Nacional de Tucuman (UNT)
Faculty of Medicine
Municipal Hospital Dresden
Arianna Foundation on Anticoagulation
Other Contributor(s)
Abstract
Background: Venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of morbidity and mortality worldwide. Methods: GARFIELD-VTE is a prospective, non-interventional observational study of real-world treatment practices. We aimed to capture the 36-month clinical outcomes of 10,679 patients with objectively confirmed VTE enrolled between May 2014 and January 2017 from 415 sites in 28 countries. Findings: A total of 6582 (61.6 %) patients had DVT alone, 4097 (38.4 %) had PE ± DVT. At baseline, 98.1 % of patients received anticoagulation (AC) with or without other modalities of therapy. The proportion of patients on AC therapy decreased over time: 87.6 % at 3 months, 73.0 % at 6 months, 54.2 % at 12 months and 42.0 % at 36 months. At 12-months follow-up, the incidences (95 % confidence interval [CI]) of all-cause mortality, recurrent VTE and major bleeding were 6.5 (7.0–8.1), 5.4 (4.9–5.9) and 2.7 (2.4–3.0) per 100 person-years, respectively. At 36-months, these decreased to 4.4 (4.2–4.7), 3.5 (3.2–2.7) and 1.4 (1.3–1.6) per 100 person-years, respectively. Over 36-months, the rate of all-cause mortality and major bleeds were highest in patients treated with parenteral therapy (PAR) versus oral anti-coagulants (OAC) and no OAC, and the rate of recurrent VTE was highest in patients on no OAC versus those on PAR and OAC. The most frequent cause of death after 36-month follow-up was cancer (n = 565, 48.6 %), followed by cardiac (n = 94, 8.1 %), and VTE (n = 38, 3.2 %). Most recurrent VTE events were DVT alone (n = 564, 63.3 %), with the remainder PE, (n = 236, 27.3 %), or PE in combination with DVT (n = 63, 7.3 %). Interpretation: GARFIELD-VTE provides a global perspective of anticoagulation patterns and highlights the accumulation of events within the first 12 months after diagnosis. These findings may help identify treatment gaps for subsequent interventions to improve patient outcomes in this patient population.